FDA Vaccine Chief Dr. Vinay Prasad to Depart Amid Controversies

Dr. Vinay Prasad, the head of the FDA's vaccine division, will leave his position at the end of April, following a tenure marked by significant controversies, including a refusal to review a new flu vaccine from Moderna. His departure comes as the FDA faces scrutiny over its decision-making processes, particularly regarding vaccine approvals and trial data requests from companies like UniQure. Prasad's previous brief exit from the agency in July raised questions about his alignment with political pressures. The FDA has yet to announce a successor for Prasad, who has been a vocal critic of the government's pandemic response and previous FDA leadership.

Key Details: • Dr. Vinay Prasad will leave the FDA at the end of April. • Controversies include vaccine decisions and trial data scrutiny. • No replacement has been announced by FDA Commissioner Dr. Marty Makary.